Copper chelation has shown efficacy in several cancer types, and it was recently proposed as a potential adjuvant strategy to overcome BRAF-MEK1/2 inhibition gained resistance in melanoma and colon cancer [46, 47]. This evidence concerns the gene MAP2K1 and colonic neoplasm.